Ewa Gacuta

Bialystok, PD 15276, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Diagnostic Potential of Selected Matrilysins and Stromelysins in the Diagnosis of Gynecological Malignancies Based on ROC Curve Analysis.

Diagnostic Potential of Selected Matrilysins and Stromelysins in the Diagnosis of Gynecological Malignancies Based on ROC Curve Analysis.

Journal: International journal of molecular sciences

Published: May 06, 2026

Role of Matrilysins (MMP-7, MMP-26) and Stromelysins (MMP-3, MMP-10) in Diagnosing Cervical Cancer Patients.

Role of Matrilysins (MMP-7, MMP-26) and Stromelysins (MMP-3, MMP-10) in Diagnosing Cervical Cancer Patients.

Journal: Biomedicines

Published: October 22, 2025

Diagnostic Use of Selected Metalloproteinases in Endometrioid Ovarian Cancer.

Diagnostic Use of Selected Metalloproteinases in Endometrioid Ovarian Cancer.

Journal: Biomedicines

Published: July 29, 2025

Plasma Levels of Matrilysins (MMP-7 and MMP-26) and Stromelysins (MMP-3 and MMP-10) in Diagnosis of Endometrial Cancer Patients.

Plasma Levels of Matrilysins (MMP-7 and MMP-26) and Stromelysins (MMP-3 and MMP-10) in Diagnosis of Endometrial Cancer Patients.

Journal: International journal of molecular sciences

Published: January 28, 2025

Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma.

Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma.

Journal: Cancers

Published: October 29, 2024

Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer.

Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer.

Journal: International journal of molecular sciences

Published: April 16, 2024

CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.

CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.

Journal: Cancer management and research

Published: April 09, 2023

Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.

Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.

Journal: Journal of clinical medicine

Published: February 24, 2023

Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer.

Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer.

Journal: Journal of clinical medicine

Published: September 05, 2022

Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer.

Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer.

Journal: Journal of clinical medicine

Published: September 22, 2021

Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?

Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?

Journal: Acta biochimica Polonica

Published: September 17, 2019

Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients - ROC Analysis.

Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients - ROC Analysis.

Journal: Anticancer research

Published: March 07, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026